Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
Humacyte's interim Phase 3 V012 results for the ATEV in female hemodialysis patients were accepted for a late-breaking oral presentation at ASN Kidney Week 2026 on October 22. V012 is a randomized controlled trial comparing the ATEV with autogenous arteriovenous fistula for dialysis access in women with end-stage kidney disease, presented by Dr. Prabir Roy-Chaudhury of UNC.
Key figures
- Drug Name
- ATEV (acellular tissue engineered vessel)
- Phase Of Trial
- Phase 3
- Trial id
- V012 / CLN-PRO-V012
- Abstract number
- TH-OR113
- Presentation date
- 2026-10-22
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.